Abstract:The aims of this research were to constitute and evaluate one targeting anticancer co-delivery system for both micro-molecularchemotherapeutic drugs( docetaxel,DTX) and small interfering RNA( siRNA) expressed by COX-2. The nanoparticles composed of poly( D, L-lactide-co-glycolide)( PLGA) bearing disulfide-linkaged reducible polyethyleneimine( PEIss) covered by hyaluronic acid( HA). Meanwhile,HA-PEI-PLGA nanoparticles were prepared as control. Firstly, the solvent evaporation was used to the particles which exhibited a core-shell structure with a uniform size of 150-200 nm. The cumulative drug release in two kinds of PBS media( p H 7. 4 and p H 5. 0) during 72 hours indicated that DTX-loaded nanoparticles had sustained-release effect within 24 hours.The cumulative release of DTX of HRPSP NPs in PBS p H 5. 0 was 10%-25% more than that in PBS p H 7. 4,which demonstrated that favored release of DTX from nanoparticles could be achieved in acidic tumor microenvironment. Then,the highest transfection efficiency was observed after 14-16 h incubation at N / P ratio of 40 /1.Following the saturation of CD44 receptor, the mean fluorescence intensity of HRPSP NPs from the cells decreased drastically in the case of saturation with free HA before. However,there existed no significance in the fluorescence of RPSP NPs between the cells with and without saturation with free HA,which indicated the nanoparticles’ targeting potential toward tumor cells. In the Western blot,the relative silencing efficiency of Bcl-2,bax,capase-3 and COX-2 mRNAprotein was calculated. In comparison to the control group, the silence efficiencies of bax and capase-3 were both significantly increased while that of Bcl-2 was evidently reduced,particularly in siCOX-2 / HRPSP NPs group( P < 0. 01). The similar results were obtained in the silence efficiency of COX-2 protein in which the COX-2 quantity on mRNA and protein decreased. The results suggest that the nanoparticles could achieve the synergistic effect on the combinatorial delivery of siRNA and lipophilic anti-tumor drugs.

Reducible Self-Assembling Cationic Polypeptide-Based Micelles Mediate Co-Delivery of Doxorubicin and Microrna-34a for Androgen-Independent Prostate Cancer Therapy

Co-delivery of miR-4638-5p and docetaxel based on redox-sensitive polypeptide micelles as an improved strategy for the treatment of castration-resistant prostate cancer.

Redox-responsive Micelles Self-Assembled from Multi-Block Copolymer for Co-Delivery of Sirna and Hydrophobic Anticancer Drug

Redox-sensitive Micelles Based on Retinoic Acid Modified Chitosan Conjugate for Intracellular Drug Delivery and Smart Drug Release in Cancer Therapy

Co-Delivery of Doxorubicin and Sirna with Reduction and Ph Dually Sensitive Nanocarrier for Synergistic Cancer Therapy

Reduction-sensitive mixed micelles assembled from amphiphilic prodrugs for self-codelivery of DOX and DTX with synergistic cancer therapy.

Biocompatible reduction-responsive polypeptide micelles as nanocarriers for enhanced chemotherapy efficacy in vitro

Novel polymer micelle mediated co-delivery of doxorubicin and P-glycoprotein siRNA for reversal of multidrug resistance and synergistic tumor therapy

Synergistic Effect of Reduced Polypeptide Micelle for Co-Delivery of Doxorubicin and Trail Against Drug-Resistance in Breast Cancer

Nucleolin-Targeting AS1411-Aptamer-Modified Graft Polymeric Micelle with Dual Ph/redox Sensitivity Designed to Enhance Tumor Therapy Through the Codelivery of Doxorubicin/TLR4 Sirna and Suppression of Invasion

Hyaluronic Acid-Chitosan Nanoparticles for Co-Delivery of MiR-34a and Doxorubicin in Therapy Against Triple Negative Breast Cancer.

Reduction-sensitive Micelles with Sheddable PEG Shells Self-Assembled from a Y-shaped Amphiphilic Polymer for Intracellular Doxorubicine Release.

Low-density Lipoprotein-Coupled Micelles with Reduction and Ph Dual Sensitivity for Intelligent Co-Delivery of Paclitaxel and Sirna to Breast Tumor

Intracellular Reduction‐Responsive Sheddable Copolymer Micelles for Targeted Anticancer Drug Delivery

Construction of Small-Sized, Robust, and Reduction-Responsive Polypeptide Micelles for High Loading and Targeted Delivery of Chemotherapeutics

Co-delivery of siRNA and docetaxel by hyaluronic acid modified redox-sensitive disulfide-crosslinked nanoparticles

Reduction-Degradable Polymeric Micelles Decorated with PArg for Improving Anticancer Drug Delivery Efficacy.

PEGylated Doxorubicin Prodrug-Forming Reduction-Sensitive Micelles With High Drug Loading and Improved Anticancer Therapy

Co-delivery of the autophagy inhibitor si-Beclin1 and the doxorubicin nano-delivery system for advanced prostate cancer treatment

The Promising Nanocarrier for Doxorubicin and Sirna Co-delivery by PDMAEMA-based Amphiphilic Nanomicelles.

Polymeric Hybrid Nanomicelles for Cancer Theranostics: an Efficient and Precise Anticancer Strategy for the Co-delivery of Doxorubicin/miR-34a and MR imaging.